Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
1245-0256
Nephrology (Chronic kidney disease) Phase III
- 9 weeks
- 1st site activated in Canada
1493-0002
Idiopathic Pulmonary Fibrosis Phase IIa
- 15.6 weeks
20210181 (MARITIME-1)
Obesity Phase III
- 6.4 weeks
20210181 (MARITIME-1)
Obesity Phase III
- 8.2 weeks
20230005
Prostate Cancer Phase III
- 13.4 weeks
- 1st site activated in Canada and Canadian FPI
20230222
Elevated Lipoprotein(a) Phase III
- 3.8 weeks
20230222
Elevated Lipoprotein(a) Phase III
- 8 weeks
20230222
Elevated Lipoprotein(a) Phase III
- 8.4 weeks
20230222
Elevated Lipoprotein(a) Phase III
- 11.4 weeks
20240031
Oncology Phase I
- 9.4 weeks
22143
Prostate Cancer Phase I
- 9.4 weeks
- 1st site activated in Canada
22143
Prostate Cancer Phase I
- 13.4 weeks
- 2nd site activated in Canada
22143
Prostate Cancer Phase I
- 13.4 weeks
- 3rd site activated in Canada
221611 (Crown)
HIV Phase IIIb
- 8.6 weeks
- 1st site activated in Canada
223050
Prostate Cancer Phase I/II
- 8.6 weeks
- 1st site activated in Canada
223050
Prostate Cancer Phase I/II
- 11.8 weeks
- 2nd site activated in Canada
223559
Advanced Solid Tumors Phase I/II
- 13.8 weeks
- Canadian FPI
223559
Advanced Solid Tumors Phase I/II
- 14 weeks
223674 (B7H3)
Oncology (Lung Cancer) Phase III
- 8 weeks
22419 (ASSESS)
Genetic Disorder (Alport Syndrome) Phase IIa
- 7 weeks
- 1st site activated in Canada
22419 (ASSESS)
Genetic Disorder (Alport Syndrome) Phase IIa
- 12 weeks
- 2nd site activated in Canada